Seattle Biotech Duped Investors On Drug Progress, Suit Says
By Greg Lamm · March 24, 2025, 6:20 PM EDT
Seattle's Sana Biotechnology Inc. is the target of a proposed class action filed on Monday by a shareholder who alleges the company misled investors about its ability to develop genetic therapy...
To view the full article, register now.